{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-012620","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.970101+00:00","generated_at":"2026-06-25T23:22:40.403330+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cardiff Oncology Q1 2022: cash $129.4M; mCRC trial shows improved ORR/PFS vs historical controls","bullets":["Cash, equivalents & short-term investments ~$129.4M as of Mar 31, 2022; net cash used in ops $10.2M.","R&D expense $7.2M (up $3.9M YoY); SG&A $3.9M (up $1.7M YoY) on higher CMC, headcount, stock comp.","Phase 1b/2 mCRC: 34% initial ORR, 29% confirmed at RP2D (15 mg/m²) vs historical 5-13%; mPFS 9.4 months across all doses.","Phase 2 mCRPC: 75% disease control at 12 weeks in highest dose-density arm; mutations in PTEN/MTOR linked to response.","Preclinical: onvansertib+olaparib showed significant survival benefit vs each alone in PARPi-resistant ovarian PDX models."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-012620","json":"https://secwatch.observer/filing/0001628280-22-012620.json","markdown":"https://secwatch.observer/filing/0001628280-22-012620.md","text":"https://secwatch.observer/filing/0001628280-22-012620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/0001628280-22-012620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022012620/crdf-20220505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:22:40.403330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}